Predictive biomarkers and the role of the microbiome determining response to antiinflammatory treatment in Inflammatory Bowel Disease (Crohn's disease and ulcerative colitis)

Recruiting

• Conditions: Crohn's disease; inflammatory Bowel Disease; ulcerative colitis; 10017969

• Registration Number: NL-OMON50413
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 2240

Inclusion Criteria

Crohn's disease
ulcerative colitis
Inflammatory Bowel disease

Exclusion Criteria

< 18 year
ongoing malignancy

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Determination of concentrations of cytokines and chemokines, presence of<br /><br>inflammatory cell subtypes and identification of mucosal microbiome in biopsies<br /><br>taken from patients with active IBD before/during/after the start of new<br /><br>anti-inflammatory treatment.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Determination of patients:<br /><br>- Genotype (including whole genome methylome and transcriptome)<br /><br>- Luminal microbiome<br /><br>- Serum cytokines and chemokines<br /><br>is associated with mucosal immunotype and microbiome in relationship to<br /><br>treatment response</p><br>